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Introduction {#cam4785-sec-0001}
============

Radiotherapy (RT) improves local control and overall survival in pediatric patients with brain tumors. However, cranial irradiation also increases the risk of stroke in cancer survivors. The estimated relative risk of stroke or transient ischemic attack (TIA) in pediatric cancer survivors who have received cranial RT was 8, with an incidence of 548/100,000 person‐years [1](#cam4785-bib-0001){ref-type="ref"}. Besides stroke and TIA, lacunar lesions, vascular occlusive disease including moyamoya syndrome, vascular malformations including aneurysm, and hemorrhage also can be induced by radiation [2](#cam4785-bib-0002){ref-type="ref"}. Moyamoya vasculopathy is characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches [3](#cam4785-bib-0003){ref-type="ref"}. When presenting with known associated risk factors, such as prior radiotherapy, patients with moyamoya vasculopathy are said to have moyamoya syndrome. Otherwise, they are said to have moyamoya disease. Post‐RT moyamoya syndrome, although known to be radiation related, is infrequently described in the literature. Between 1971 and 2015, there have been a total of 84 reported cases of moyamoya syndrome following cranial RT, of which 76 occurred in children [4](#cam4785-bib-0004){ref-type="ref"}, [5](#cam4785-bib-0005){ref-type="ref"}, [6](#cam4785-bib-0006){ref-type="ref"}, [7](#cam4785-bib-0007){ref-type="ref"}, [8](#cam4785-bib-0008){ref-type="ref"}, [9](#cam4785-bib-0009){ref-type="ref"}, [10](#cam4785-bib-0010){ref-type="ref"}, [11](#cam4785-bib-0011){ref-type="ref"}. The long‐term clinical outcome of these patients with post‐RT moyamoya syndrome also remains unclear. In addition, ethnic and regional differences in the incidence of moyamoya disease have been noted. In Japan, moyamoya disease is the most common pediatric cerebrovascular disease, with a prevalence of about three cases per 100,000 children [12](#cam4785-bib-0012){ref-type="ref"}, [13](#cam4785-bib-0013){ref-type="ref"}, [14](#cam4785-bib-0014){ref-type="ref"}. In the United States, incidence ratios are 4.6 for Asians, 2.2 for African‐Americans, and 0.5 for Hispanics, compared with Caucasians [15](#cam4785-bib-0015){ref-type="ref"}. Incidence per 100,000 patient‐years ranged in Japan from 0.35--0.94, 0.15 in Taiwan, in the United States from 0.05 in Iowa to 0.17 in Hawaii, and 0.41 in Nanjing, China [16](#cam4785-bib-0016){ref-type="ref"}, [17](#cam4785-bib-0017){ref-type="ref"}. It is unknown whether the incidence of RT‐related moyamoya syndrome has regional or interethnic difference. In this study, we investigated the incidence and long‐term clinical outcome of moyamoya syndrome in pediatric patients with primary brain tumors treated with cranial RT.

Materials and Methods {#cam4785-sec-0002}
=====================

Taipei Veterans General Hospital (TVGH) has been dedicated to the treatment of pediatric patients with brain tumors for more than 30 years [18](#cam4785-bib-0018){ref-type="ref"}. With 100--150 new cases each year in Taiwan, more than 986 cases were treated in TVGH from 1975 to May 2004 [19](#cam4785-bib-0019){ref-type="ref"}. All patients were treated and followed by the same team, comprised of pediatric neurosurgeons, pathologists, neuroradiologists, pediatric neuro‐oncologists, and radiation oncologists. To improve the efficiency of management and use of clinical data, an electronic registry system was established in 2008. According to this registry, between January 1975 and December 2005, there were 564 pediatric patients with brain tumors who received cranial RT in TVGH. However, complete RT notes and follow‐up imaging were only available in 391 cases (69.3%). The demographic data of these patients are listed in Table [1](#cam4785-tbl-0001){ref-type="table-wrap"}. All patients were residents of Taiwan, and none had a first‐degree relative with moyamoya disease. The median follow‐up period was 7.3 years. Forty of the patients received repeated RT of different course. Only the physical doses of the first courses are listed in the median doses reported.

###### 

Patient demographic data

  Diagnosis                                                               No. of cases   Mortality   Median age (year)   Median RT dose (cGy)
  ----------------------------------------------------------------------- -------------- ----------- ------------------- ----------------------
  Medulloblastoma                                                         100            54          7                   5130
  Atypical teratoid/rhabdoid tumors                                       18             12          4.3                 5000
  PNET[a](#cam4785-note-0003){ref-type="fn"}                              6              4           5.5                 4842
  Optic glioma (grade 1)                                                  6              2           5.5                 5069
  Pilocytic astrocytoma[b](#cam4785-note-0004){ref-type="fn"} (grade 1)   20             5           10.5                5517.5
  Astrocytoma (grade 2)                                                   19             4           10                  5508
  Oligodendroglioma (grade 2)                                             5              2           11                  5613
  Ependymoma (grade 2)                                                    8              6           5.5                 4673
  Anaplastic astrocytoma (grade 3)                                        36             24          10                  6237
  Anaplastic ganglioglioma (grade 3)                                      1              0           7                   6400
  Anaplastic ependymoma (grade 3)                                         7              2           9                   5300
  Glioblastoma (grade 4)                                                  17             12          10.5                5600.5
  Ependymoblastoma (grade 4)                                              1              0           14                  5260
  Astroblastoma (grade 4)                                                 1              1           8                   5573
  Brain stem tumor (without pathological diagnosis)                       35             23          8                   6573
  Germinoma                                                               66             8           13                  3800
  Other germ cell tumors[c](#cam4785-note-0005){ref-type="fn"}            16             4           10                  5109
  Meningioma                                                              5              3           12                  5804
  Craniopharyngioma                                                       24             3           9                   5400
  Total                                                                   391            169                             

RT, Radiotherapy

This number includes two patients with pineoblastoma.

Other than optic glioma.

This category includes five patients with yolk sac tumors, three patients with mature teratomas, one patient with an immature teratoma, one patient with an unclassified germ cell tumor, and six patients with mixed germ.
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A post‐RT stroke or TIA occurred in 13 of the 391 patients listed in Table [1](#cam4785-tbl-0001){ref-type="table-wrap"}. A neuroradiologist reviewed medical imaging of these cases to determine whether any had moyamoya vasculopathy. The incidence was calculated by number of patients with post‐RT moyamoya syndrome divided by the total follow‐up person‐years for each diagnosis of a primary brain tumor. Kaplan--Meier survival analysis was used to estimate the cumulative incidence, and the log‐rank test was used to compare the cumulative incidence between different diagnoses. To compare the crude incidence of different diagnoses from other published series, a two‐tailed Fisher\'s exact test was used. Statistical analyses were performed using SPSS Statistics version 20 (IBM, Armonk, NY). All *P*‐values less than 0.05 were considered significant. This study was approved by the hospital\'s institutional review board.

Results {#cam4785-sec-0003}
=======

Among the 13 patients with post‐RT stroke or TIA, nine were found to have moyamoya vasculopathy. One patient, a 5‐year‐old girl with optic glioma and neurofibromatosis type‐1 (NF1) was found with moyamoya vasculopathy before radiotherapy based on a postoperative MRI and was thus excluded. The remaining eight patients had received angiography for suspected moyamoya syndrome. Their clinical characteristics are listed in Table [2](#cam4785-tbl-0002){ref-type="table-wrap"}. The median latency was 3 years post‐RT. Of the 391 patients included, follow‐up of more than 3 years was achieved in 235 (60.1%) of them. More than 10 years follow‐up was reached in 162 (41.4%) patients.

###### 

Characteristics of pediatric patients with post‐RT moyamoya syndrome (MMS)

  Diagnosis           Sex; age at RT (year)   MMS latency (year)   RT dose (cGy)/site       Symptoms                                            NF[a](#cam4785-note-0007){ref-type="fn"}   U/B[b](#cam4785-note-0008){ref-type="fn"}   A/P[c](#cam4785-note-0009){ref-type="fn"}   Bypass[d](#cam4785-note-0010){ref-type="fn"}   Recurrent TIA/stroke   Outcome[e](#cam4785-note-0011){ref-type="fn"}
  ------------------- ----------------------- -------------------- ------------------------ --------------------------------------------------- ------------------------------------------ ------------------------------------------- ------------------------------------------- ---------------------------------------------- ---------------------- -----------------------------------------------
  Astrocytoma         M; 15                   4                    5400/suprasellar         Int. gen. weakness, drowsiness for 6 months.        --                                         B                                           A                                           \+                                             --                     Independent
  Optic glioma        M; 6                    2                    4000/suprasellar         Int. gen. weakness, conscious change for 1 month.   \+                                         B                                           A                                           --[f](#cam4785-note-0012){ref-type="fn"}       --                     Died of brain tumor
  Craniopharyngioma   M; 7                    2                    4500/sellar              L hand mild numbness, clumsy for 8 months.          --                                         B                                           A                                           \+                                             --                     Dependent, stable
  Medulloblastoma     F; 9                    14                   5000/p. fossa; 3600/CS   sudden L limb weakness                              --                                         U                                           A                                           \+                                             --                     Died of brain tumor
  Medulloblastoma     F; 9                    20                   5208/p. fossa; 3954/CS   Acute slurred speech                                --                                         B                                           AP                                          --[g](#cam4785-note-0013){ref-type="fn"}       \+                     Dependent, stable
  Craniopharyngioma   M; 10                   3                    5040/sellar              Noted in follow‐up MRI                              --                                         B                                           AP                                          --[f](#cam4785-note-0012){ref-type="fn"}       --                     Died of brain tumor
  Craniopharyngioma   F; 2                    2                    5400/sellar              Sudden R hemiplegia, consciousness disturbance      --                                         U                                           A                                           --[h](#cam4785-note-0014){ref-type="fn"}       \+                     Dependent, deteriorated
  Optic glioma        M; 7                    3                    5098/suprasellar         Sudden L hemiplegia, aphasia, R facial palsy        --                                         B                                           A                                           ‐[h](#cam4785-note-0014){ref-type="fn"}        --                     Dependent, stable

M, male; F, female; p, posterior; CS, craniospinal (axis); L, left; R, right; Sudden implies sudden onset; RT, radiotherapy; TIA, transient ischemic attack.

\+ indicates that the patient was diagnosed with type‐1 neurofibromatosis.

Unilateral/bilateral.

Anterior/posterior circulation.

\+ indicates that the patient received bypass surgery after moyamoya syndrome diagnosis.

Independent: lives independently; stable: neurological function stable compared with the function prior to moyamoya syndrome; deteriorated: neurological function deteriorated compared with the function when first diagnosed with moyamoya syndrome. Patient is alive unless otherwise indicated.

Bypass surgery not performed due to progressive brain tumor.

Bypass surgery not performed due to TIA only.

Bypass surgery not performed due to poor neurological condition.
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The total follow‐up person‐years and number of patients with moyamoya vasculopathy by disease were, respectively, optic glioma (51, 2), craniopharyngioma (231, 3), astrocytoma (288, 1), and medulloblastoma (1023, 2). The incidence for each type of brain tumor after receiving RT, in person‐years, was thus 0.039 for optic glioma, 0.013 for craniopharyngioma, 0.003 for astrocytoma, and 0.002 for medulloblastoma.

Based on the survival analysis, there was a significant difference (*P* = 0.002) in cumulative incidence of moyamoya vasculopathy in patients with different types of brain tumor after RT. The cumulative incidence of this condition by disease at 7 years was: optic glioma, 40% (standard error: 21.9%); craniopharyngioma, 14.8% (7.9%); astrocytoma, 6.2% (6.1%); and medulloblastoma, 0 (Fig. [1](#cam4785-fig-0001){ref-type="fig"}). The crude incidence of post‐RT moyamoya syndrome by diagnosis was: 2/6 (33.3%) for optic glioma, 3/24 (12.5%) for craniopharyngioma, 2/100 (2%) for medulloblastoma, and 1/19 (5.3%) for astrocytoma.

![Cumulative incidence of postradiotheraphy moyamoya syndrome.](CAM4-5-2155-g001){#cam4785-fig-0001}

No patients died as a direct result of post‐RT moyamoya syndrome. There were three deaths: two patients died of recurrent tumor, and one died of adrenal crisis. In the three patients who underwent bypass surgery, the neurological function of the two remained stable compared with their function prior to developing moyamoya syndrome, and the other died of recurrent tumor. Two patients did not undergo bypass surgery because of poor disease prognosis. Bypass surgery was not performed in two patients because they only had TIAs. The reason for not performing bypass surgery for the remaining patient is unknown. Recurrent stroke occurred in two of the five patients not undergoing bypass surgery, causing deteriorated neurological function in one of them.

Discussion {#cam4785-sec-0004}
==========

We estimated the incidence of post‐RT moyamoya syndrome in pediatric patients who had been treated for different types of primary brain tumors, finding that the incidence differed among diagnoses. Post‐RT moyamoya syndrome was not routinely fatal. However, repeated cerebral vascular events happened in those who did not undergo surgery.

Post‐RT moyamoya syndrome is a rare condition, and most publications on the subject are case reports or series that provide no estimate of incidence. This study is the first investigation on the incidence and long‐term outcome of this rare complication of RT. Given the ethnic homogeneity in Taiwan, the influence of ethnicity may make comparisons to other series challenging.

The etiology of moyamoya disease remains unknown. Known factors associated with moyamoya syndrome include sickle cell disease, NF1, therapeutic cranial irradiation, Down syndrome, congenital cardiac anomaly, renal‐artery stenosis, giant cervicofacial hemangiomas, and hyperthyroidism [3](#cam4785-bib-0003){ref-type="ref"}. A study based on 54 published cases of radiation‐induced moyamoya syndrome found that 29 (53.7%) arose following a diagnosis of optic glioma. This finding is consistent with our result that the highest incidence was found in those with optic glioma. The reason for the high incidence in this diagnosis may be from high‐dose radiation given to the suprasellar region, which contains circle of Willis. Moreover, optic glioma is associated with NF1. Patients with NF1 who received higher doses of radiation to the circle of Willis have increased risk of moyamoya syndrome development [11](#cam4785-bib-0011){ref-type="ref"}.

Craniopharyngioma arises inside the sella turcica. The circle of Willis would also be exposed to considerable scattered doses of radiation when this tumor is treated with RT, hence increasing the risk of complications. The only case of astrocytoma with post‐RT moyamoya syndrome was also the only one located in the suprasellar region, and that patient received a high dose of RT to the circle of Willis. Of the eight patients in the study, the high‐dose RT covered the suprasellar region in three and the sellar region in another three. However, in two cases of medulloblastoma, high‐dose RT was prescribed only to the posterior fossa surgical bed, and the radiation dose to the circle of Willis came only from low‐dose RT to the craniospinal axis. The latencies of moyamoya syndrome after RT in these two cases were longer than the other six cases. With the long‐term follow‐up in our study, we were able to identify a considerable incidence of moyamoya syndrome in those who only received low‐dose RT to the circle of Willis. Therefore, lower doses of radiotherapy might also induce moyamoya syndrome after a long latency.

In a study of pediatric patients with primary brain tumors treated at the Dana‐Farber Cancer Institute between 1990 and 2000, the crude incidence of post‐RT moyamoya syndrome was found to be 9/31 (29%) for optic glioma, 1/23 (4.3%) for craniopharyngioma, and 1/65 (1.5%) for medulloblastoma [11](#cam4785-bib-0011){ref-type="ref"}. Those data are not significantly different from those of this study. None of the patients in the Dana‐Faber study were of Asian descent, while all patients in this study were ethnic Taiwanese.

The crude incidence of post‐RT moyamoya syndrome in pediatric patients with craniopharyngioma was found to be 2/15 (13.3%) in a Korean series [8](#cam4785-bib-0008){ref-type="ref"}. That crude incidence is not different from the crude incidence found in this study.

Published data suggests that surgical revascularization is a safe intervention for pediatric moyamoya syndrome, and most treated patients derive some symptomatic benefit [20](#cam4785-bib-0020){ref-type="ref"}. In this study, a favorable outcome after bypass surgery was also found in patients with post‐RT moyamoya syndrome. Thus, surgical revascularization should be considered first for these patients. Based on this study, screening magnetic resonance angiography (MRA) on patients treated with RT, especially in cases of optic glioma and craniopharyngioma, may be worthwhile, for the high incidence and potential benefits of timely surgical intervention of early diagnosis.

Limitation of the study {#cam4785-sec-0005}
-----------------------

Only 69.3% of patients receiving radiation for brain tumors had complete notes and follow‐up imaging, potentially compromising the results. Only those patients with stroke or TIA were assessed for moyamoya syndrome, potentially omitting early cases, though one case was identified on routine imaging. Radiotherapy dose to the vasculature was not estimated, as we could not reliably estimate the scattered radiation dose from the two‐dimensional Cobalt‐60 plan.

Conclusion {#cam4785-sec-0006}
==========

The incidence of post‐RT moyamoya syndrome in pediatric patients in Taiwan with each type of primary brain tumor was estimated. The incidence differed among diagnoses, with the highest incidence noted in optic glioma. The crude incidence was not different from those reported in two other series, from the United States and Korea. The clinical outcome is usually favorable. Stable long‐term neurological function may be achieved after timely surgical intervention.
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